| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CGEM
Cullinan Management
|
Jun 08, 2026 | BUY |
Strong Buy
+132.3% avg upside
15 analysts
|
$28.00
83.31% Upside
|
+8.7% |
|
ARGX
Argenx Se
|
May 29, 2026 | BUY |
Strong Buy
-16.4% avg upside
46 analysts
|
$1255.00
42.51% Upside
|
+5.6% |
|
EQ
Equillium
|
May 28, 2026 | BUY |
Strong Buy
+185.0% avg upside
14 analysts
|
$5.00
64.11% Upside
|
-2.5% |
|
IMVT
Immunovant
|
May 25, 2026 | BUY |
Strong Buy
+11.1% avg upside
24 analysts
|
$49.00
40.59% Upside
|
+2.6% |
|
AVTX
Avalo Therapeutics
|
May 15, 2026 | BUY |
Strong Buy
+252.5% avg upside
19 analysts
|
$39.00
159.47% Upside
|
-7.8% |
|
VRDN
Viridian Therapeutics
|
May 13, 2026 | BUY |
Strong Buy
+102.9% avg upside
32 analysts
|
$39.00
135.35% Upside
|
-5.5% |
|
SYRE
Spyre Therapeutics
|
May 12, 2026 | BUY |
Strong Buy
-14.3% avg upside
23 analysts
|
$107.00
22.11% Upside
|
+11.4% |
|
ACRS
Aclaris Therapeutics
|
May 08, 2026 | HOLD |
Strong Buy
+125.8% avg upside
15 analysts
|
$4.00
9.38% Downside
|
-12.4% |
|
ASND
Ascendis Pharma
|
May 08, 2026 | BUY |
Strong Buy
+16.5% avg upside
24 analysts
|
$328.00
41.45% Upside
|
-6.4% |
|
CRNX
Crinetics Pharmaceuticals
|
May 08, 2026 | BUY |
Strong Buy
+122.6% avg upside
20 analysts
|
$83.00
134.00% Upside
|
-11.2% |
|
JBIO
Jade Biosciences
|
May 07, 2026 | BUY |
Strong Buy
+233.0% avg upside
16 analysts
|
$40.00
136.92% Upside
|
-35.9% |
|
TVTX
Travere Therapeutics
|
May 05, 2026 | HOLD |
Strong Buy
-14.7% avg upside
22 analysts
|
$43.00
20.94% Downside
|
+16.2% |
|
SEPN
Septerna, Inc.
|
May 01, 2026 | BUY |
Strong Buy
+19.4% avg upside
12 analysts
|
$43.00
21.06% Upside
|
+28.8% |
|
EVMN
Evommune, Inc.
|
May 01, 2026 | BUY |
Strong Buy
+144.9% avg upside
12 analysts
|
$54.00
165.50% Upside
|
-18.2% |
|
ORKA
Oruka Therapeutics
|
Apr 28, 2026 | BUY |
Strong Buy
+62.9% avg upside
16 analysts
|
$150.00
105.71% Upside
|
-5.5% |
|
PALI
Palisade Bio
|
Apr 04, 2026 | BUY |
Strong Buy
+1425.2% avg upside
15 analysts
|
$5.00
166.65% Upside
|
-8.8% |
|
ALMS
Alumis Inc.
|
Apr 04, 2026 | BUY |
Strong Buy
+66.0% avg upside
11 analysts
|
$44.00
90.62% Upside
|
+8.8% |
|
APGE
Apogee Therapeutics
|
Mar 23, 2026 | BUY |
Strong Buy
+31.2% avg upside
19 analysts
|
— | +11.6% |
|
DNTH
Dianthus Therapeutics
|
Mar 10, 2026 | BUY |
Strong Buy
+9.8% avg upside
29 analysts
|
$120.00
46.03% Upside
|
-9.2% |
|
ANAB
AnaptysBio
|
Mar 05, 2026 | BUY |
Strong Buy
+28.1% avg upside
26 analysts
|
$85.00
48.53% Upside
|
+50.9% |
|
MLTX
MoonLake Immunotherapeutics
|
Mar 01, 2026 | HOLD |
Strong Buy
+51.0% avg upside
20 analysts
|
$19.00
1.75% Downside
|
+8.5% |
|
CLDX
Celldex
|
Feb 26, 2026 | BUY |
Strong Buy
+18.8% avg upside
28 analysts
|
$68.00
108.48% Upside
|
+5.6% |
|
KYMR
Kymera Therapeutics
|
Dec 15, 2025 | BUY |
Strong Buy
+9.5% avg upside
36 analysts
|
$114.00
26.92% Upside
|
-0.1% |
|
PLRX
Pliant Therapeutics
|
Mar 03, 2025 | HOLD |
Buy
+1806.3% avg upside
21 analysts
|
$3.00
161.94% Upside
|
-9.4% |
|
HLIT
Harmonic
|
Nov 07, 2024 | BUY |
Buy
-12.4% avg upside
14 analysts
|
$23.00
52.91% Upside
|
-16.2% |
|
APOG
Apogee
|
Aug 08, 2023 | BUY |
Strong Buy
+14.6% avg upside
7 analysts
|
$34.00
18.84% Downside
|
+25.8% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.